頁籤選單縮合
題 名 | Treatment for Erectile Dysfunction in the Elderly Using Phosphodiesterase Type Ⅴ Inhibitors=磷酸二酯酶第五型抑制劑治療老年人的勃起功能障礙 |
---|---|
作 者 | 簡邦平; | 書刊名 | 臺灣老年醫學暨老年學雜誌 |
卷 期 | 8:3 2013.08[民102.08] |
頁 次 | 頁147-159 |
分類號 | 417.7722 |
關鍵詞 | 勃起功能障礙; 磷酸二酯酶第5型抑製劑; 性功能障礙; Erectile dysfunction; Phosphodiesterase type 5 inhibitor; Sexual dysfunction; |
語 文 | 英文(English) |
中文摘要 | v勃起功能障礙是男性常見的疾病,盛行率跟慢性病息息相關,例如糖尿病、高血壓、高脂血症與憂鬱症。因為年齡愈高,罹患這些危險因子的機會也愈高,勃起功能障礙的盛行率因此跟年齡增加呈高度相關。由於老年人口增加、愈來愈重視生活品質、口服治療藥物的成功與性功能障礙的高盛行率,勃起功能障礙疾病對經濟社會的影響,未來會持續增加。口服磷酸二酯酶第5型抑製劑是勃起功能障礙的第一線治療選擇,也是最常使用的方式。許多臨床藥物試驗證實磷酸二酯酶第5型抑製劑的安全性和有效性,治療對象包括糖尿病,高血壓,冠狀動脈疾病等的一般族群,以及年齡超過65歲的老年族群。勃起功能是心血管疾病的併發症,同時也是心血管疾病的早期標誌。目前並無證據顯示,治療勃起功能障礙會增加心血管疾病患者的心血管風險。 |
英文摘要 | Erectile dysfunction (ED) is a prevalent medical disease associated with various chronic diseases, including diabetes, hypertension, dyslipidemia and depression. The prevalence of ED is strongly correlated with increasing age because people might develop more risk factors for ED when they grow old. With an aging world population, greater concerns for quality of life, success of oral therapy for ED, and amounting prevalence of sexual dysfunction, the economic burden of ED is expect to continue aggravating in the future. Oral phosphodiesterase type 5 (PDE5) inhibitor is recommended as the first-line treatment choice for ED and is the most popular form of treatment. Many clinical trials have demonstrated the efficacy and safety of PDE5 inhibitors in both general and elderly patients with various comorbidities, such as diabetes, hypertension, and coronary artery disease. ED is not only a consequence but also a precursor of cardiovascular diseases. There is, however, no evidence that treating ED in patients with cardiovascular diseases increases cardiac risk. |
本系統中英文摘要資訊取自各篇刊載內容。